TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02425254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Description: 1000mg intravenous solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous saline 0.9%
Description: 0.9% sodium chloride in order to ensure double-blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous saline 0.9%
Description: 0.9% sodium chloride in order to ensure double-blinding
Study: NCT01048463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDEPA
Description: The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDEPA
Description: The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
Study: NCT02399631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery program
Description: Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
Study: NCT03143387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries removal using only manual instruments
Description: Caries removal using only manual instruments according to Atraumatic Restorative Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caries removal using Papacarie gel
Description: Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
Study: NCT03309917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP set at 80-85 mmHg for 5 min
Description: MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP set at 70-75 mmHg for 5 min
Description: MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP set at 60-65 mmHg for 5 min
Description: MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
Study: NCT01162278

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: Single fraction SBRT
Study: NCT01514825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT04135209

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography OCTA
Description: Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography OCTA
Description: Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
Study: NCT04716166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-oriented incentive spirometry
Description: 3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
Study: NCT01691872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Retigabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: Retigabine
Study: NCT03478319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-2494 or placebo
Description: Recombination fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-2494 or placebo
Description: Recombination fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-2494 or placebo
Description: Recombination fusion protein
Study: NCT00786448

Intervention type: DRUG
Intervention: Darifenacin, Emselex (BAY79-4998)
Description: Patients from routine practice
Study: NCT02001168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh-Endostatin
Description: rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
Study: NCT02001168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-platinum
Description: Cis-platinum 60mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-platinum
Description: Cis-platinum 60mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-platinum
Description: Cis-platinum 60mg/m2, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-platinum
Description: Cis-platinum 60mg/m2, d1, 21 d as a cycle.
Study: NCT01202695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-21D9
Description: intravenously, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04542928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse facilitated face care group
Description: The experimental group is required to receive a nurse leading 50- minute face care group every two week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: nurse facilitated face care group
Description: The experimental group is required to receive a nurse leading 50- minute face care group every two week
Study: NCT03888755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Participants will receive icatibant 30 mg SC injection in the abdominal area.
Study: NCT00982033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren
Description: aliskiren 300mg qd versus placebo for 24 weeks.
Study: NCT03650452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 tablets or mini-tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching tablets or mini-tablets.
Study: NCT02969317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: Fixed dose combination
Study: NCT04573452

Intervention type: DIAGNOSTIC_TEST
Intervention: Galectin-3
Description: Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Galectin-3
Description: Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Placental Galactin-3
Description: Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Placental Galactin-3
Description: Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
Study: NCT02728258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02678741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLPLDC Vaccine
Description: Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLPLDC Vaccine
Description: Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLPLDC Vaccine
Description: Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
Study: NCT00982033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo qd for 24 weeks
Study: NCT02119884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
Study: NCT06054022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasoprong oxyen 2Litres per minute
Description: nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
Study: NCT04892758

Intervention type: DRUG
Intervention: Formoterol fumarate 10 mcg
Description: Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
Study: NCT03677999

Intervention type: DIAGNOSTIC_TEST
Intervention: MEGA-PRESS sequence Magnetic Resonance Spectroscopy
Description: MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
Study: NCT01514825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT00852917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.
Study: NCT04892758

Intervention type: DRUG
Intervention: Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Description: Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
Study: NCT03503682

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study: NCT01503060

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational video - Active
Description: The active video will instruct parents in techniques related to optimal infant soothing.
Study: NCT00852917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Description: One Tramadol Once A Day tablet at randomized dose daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet daily.
Study: NCT01503060

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational video - Active
Description: The active video will instruct parents in techniques related to optimal infant soothing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational video - Active
Description: The active video will instruct parents in techniques related to optimal infant soothing.
Study: NCT02412462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-16B5
Study: NCT01503060

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational Video - Sham
Description: The sham video will provide general information about immunization immunization pain management.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose Placebo (water)
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose Placebo (water)
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
Study: NCT02504814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Highflow (NHF)
Description: changes in breathing physiology in NHF
Study: NCT01610063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic algorithm
Description: Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
Study: NCT01503060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Placebo
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Placebo
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Placebo
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
Study: NCT01111539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded capsule
Description: Blinded capsule administered orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded capsule
Description: Blinded capsule administered orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded capsule
Description: Blinded capsule administered orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded capsule
Description: Blinded capsule administered orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded capsule
Description: Blinded capsule administered orally, once daily.
Study: NCT03539458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement
Study: NCT02738437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kryptonite-bone cement
Study: NCT01333267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone-related Protein (1-36)
Description: PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parathyroid hormone (1-34)
Description: PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH (1-34) and PTHrP (1-36)
Description: This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH (1-34) and PTHrP (1-36)
Description: This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
Study: NCT03537820

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire EVAN-G

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire EVAN-G
Study: NCT01826422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA and DHA
Description: Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
Study: NCT03443726

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block technique
Description: Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltrative technique
Description: Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% articaine 1:100.000 epinephrine
Description: Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% articaine 1:100.000 epinephrine
Description: Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar extraction
Description: Third molar extraction under local anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction
Description: Third molar extraction under local anesthesia.
Study: NCT01536977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo BBT-I

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo BBT-I
Study: NCT04760119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein bypass surgery first strategy
Description: Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment first (drug coated balloon angioplasty) strategy
Description: Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
Study: NCT01830010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Part 1: KRP203
Description: All subjects will receive KRP203 for 111 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Part 2: KRP203 lower dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Part 2: KRP203 higher dose
Study: NCT02001714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Behavioral Treatment
Description: Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
Study: NCT02209740

Intervention type: OTHER
Intervention: Tenofovir switch
Description: Patients switched tenofovir to different antiretroviral regimen according to physicians decision
Study: NCT04089488

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Correlative studies

Intervention type: OTHER
Intervention: Survey Administration
Description: Respond to surveys
Study: NCT01818778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program
Description: The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Friendly Visit
Description: Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident.